UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Eosinophilic esophagitis and symptoms possibly related to eosinophilic esophagitis in oral immunotherapy

Annals of allergy, asthma, & immunology, 2018-03, Vol.120 (3), p.237-240.e4

2018

Volltextzugriff (PDF)

Use of omalizumab for management of idiopathic anaphylaxis: A systematic review and retrospective case series

Annals of allergy, asthma, & immunology, 2021-10, Vol.127 (4), p.481-487

2021

Volltextzugriff (PDF)

Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results

Journal of allergy and clinical immunology, 2020-10, Vol.146 (4), p.863-874

2020

Volltextzugriff (PDF)

Omalizumab for chronic urticaria in children younger than 12 years

Annals of allergy, asthma, & immunology, 2019-08, Vol.123 (2), p.208-210.e2

2019

Volltextzugriff (PDF)

Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy

JCI insight, 2019-11, Vol.4 (22)

2019

Volltextzugriff (PDF)

From clinical observations and molecular dissection to novel therapeutic strategies for primary immunodeficiency disorders

American journal of medical genetics. Part A, 2018-04, Vol.176 (4), p.784-803

2018

Volltextzugriff (PDF)

Identification of mast cell progenitor cells in the airways of individuals with allergic asthma

Allergy (Copenhagen), 2023-02, Vol.78 (2), p.547-549

2023

Volltextzugriff (PDF)

Clinical response to omalizumab in patients with hereditary α-tryptasemia

Annals of allergy, asthma, & immunology, 2020-01, Vol.124 (1), p.99-100.e1

2020

Volltextzugriff (PDF)

Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab

Clinical and experimental allergy, 2021-12, Vol.51 (12), p.1648-1652

2021

Volltextzugriff (PDF)

Extracellular vesicle microRNAs as predictors of response to omalizumab in chronic spontaneous urticaria

Allergy (Copenhagen), 2021-04, Vol.76 (4), p.1274-1277

2021

Volltextzugriff (PDF)

Approach to the evaluation of adverse antibiotic reactions in patients with cystic fibrosis

Annals of allergy, asthma, & immunology, 2016-10, Vol.117 (4), p.378-381

2016

Volltextzugriff (PDF)

Resolution of Severe Near Fatal Food Allergy Following Hematopoietic Stem Cell Transplantation

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB400-AB400

2016

Volltextzugriff (PDF)

Abnormal Newborn SCID Screen and Lymphopenia in an Infant Exposed to in Utero Folfirinox Chemotherapy

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB23-AB23

2016

Volltextzugriff (PDF)

Trends in Adverse Reactions Requiring Epinephrine in the Build-up Phase of Oral Immunotherapy

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB131-AB131

2016

Volltextzugriff (PDF)

Combination Omalizumab and Intravenous Immunoglobulin (IVIG) as successful treatment of common variable immunodeficiency (CVID) and severe persistent asthma

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB215-AB215

2017

Volltextzugriff (PDF)

Low-dose methylmercury-induced oxidative stress, cytotoxicity, and tau-hyperphosphorylation in human neuroblastoma (SH-SY5Y) cells

Environmental toxicology, 2012-09, Vol.27 (9), p.549-555

2012

Volltextzugriff (PDF)

Prevalence and Characteristics of Atopic Conditions in the Pacific Northwest United States

Journal of allergy and clinical immunology, 2024-02, Vol.153 (2), p.AB54

2024

Volltextzugriff (PDF)

FDA-approved peanut allergy treatment

Annals of allergy, asthma, & immunology, 2018-08, Vol.121 (2), p.145-149

2018

Volltextzugriff (PDF)

Effect of Needle-Free Epinephrine on Food Allergy Patient and Caregiver Quality of Life

Journal of allergy and clinical immunology, 2024-02, Vol.153 (2), p.AB80

2024

Volltextzugriff (PDF)

Clinical outcomes of patients with idiopathic anaphylaxis receiving omalizumab

Journal of allergy and clinical immunology, 2021-02, Vol.147 (2), p.AB16-AB16

2021

Volltextzugriff (PDF)

Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome: An Adverse Effect in a Patient With Atopic Dermatitis

Cutis, 2023-03, Vol.111 (3), p.E5-E6

2023

Volltextzugriff (PDF)

Acute Food Protein-Induced Enterocolitis Syndrome (FPIES) In The Pacific Northwest: Lessons From 129 Patients In A Private Practice Group

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB52

2020

Volltextzugriff (PDF)

FDA-approved peanut allergy treatment: The first wave is about to crest

Annals of allergy, asthma, & immunology, 2018-08, Vol.121 (2), p.145-149

2018

Volltextzugriff (PDF)

Treatment of Single and Multiple Food Allergies with ADP101: Results of the Harmony Phase 1/2 Trial

Journal of allergy and clinical immunology, 2024-02, Vol.153 (2), p.AB240

2024

Volltextzugriff (PDF)

1 – 25 von 96

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(87)

Publikationsform

Sprache

Englisch
(96)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Eosinophilic esophagitis and symptoms possibly related to eosinophilic esophagitis in oral immunotherapy

Use of omalizumab for management of idiopathic anaphylaxis: A systematic review and retrospective case series

Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results

Omalizumab for chronic urticaria in children younger than 12 years

Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy

From clinical observations and molecular dissection to novel therapeutic strategies for primary immunodeficiency disorders

Identification of mast cell progenitor cells in the airways of individuals with allergic asthma

Clinical response to omalizumab in patients with hereditary α-tryptasemia

Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab

Extracellular vesicle microRNAs as predictors of response to omalizumab in chronic spontaneous urticaria

Approach to the evaluation of adverse antibiotic reactions in patients with cystic fibrosis

Resolution of Severe Near Fatal Food Allergy Following Hematopoietic Stem Cell Transplantation

A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals

Abnormal Newborn SCID Screen and Lymphopenia in an Infant Exposed to in Utero Folfirinox Chemotherapy

Trends in Adverse Reactions Requiring Epinephrine in the Build-up Phase of Oral Immunotherapy

Combination Omalizumab and Intravenous Immunoglobulin (IVIG) as successful treatment of common variable immunodeficiency (CVID) and severe persistent asthma

Low-dose methylmercury-induced oxidative stress, cytotoxicity, and tau-hyperphosphorylation in human neuroblastoma (SH-SY5Y) cells

Prevalence and Characteristics of Atopic Conditions in the Pacific Northwest United States

FDA-approved peanut allergy treatment

Effect of Needle-Free Epinephrine on Food Allergy Patient and Caregiver Quality of Life

Clinical outcomes of patients with idiopathic anaphylaxis receiving omalizumab

Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome: An Adverse Effect in a Patient With Atopic Dermatitis

Acute Food Protein-Induced Enterocolitis Syndrome (FPIES) In The Pacific Northwest: Lessons From 129 Patients In A Private Practice Group

FDA-approved peanut allergy treatment: The first wave is about to crest

Treatment of Single and Multiple Food Allergies with ADP101: Results of the Harmony Phase 1/2 Trial

Suchergebnisse filtern